We are live on
!
Find out more
Iovance Biotherapeutics
IOVA
IOVA
228 hedge funds and large institutions have $1.25B invested in Iovance Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 87 increasing their positions, 65 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 29
34% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 65
15% more capital invested
Capital invested by funds: $1.1B → $1.25B (+$159M)
12% more call options, than puts
Call options by funds: $6.36M | Put options by funds: $5.67M
5% more funds holding
Funds holding: 218 → 228 (+10)
18.12% less ownership
Funds ownership: 109.66% → 91.54% (-18%)
Holders
228
Holders Change
+10
Holders Change %
+4.59%
% of All Funds
3.63%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
40
Increased
87
Reduced
65
Closed
29
Calls
$6.36M
Puts
$5.67M
Net Calls
+$682K
Net Calls Change
-$4.6M
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$60.7M |
| 2 |
PA
Perceptive Advisors
New York
|
+$37M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$18.8M |
| 4 |
Morgan Stanley
New York
|
+$18.8M |
| 5 |
O
OrbiMed
New York
|
+$18.6M |
Top Sellers
| 1 |
D.E. Shaw & Co
New York
|
-$12.8M |
| 2 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$9.88M |
| 3 |
Renaissance Technologies
New York
|
-$9.14M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$8.06M |
| 5 |
State Street
Boston,
Massachusetts
|
-$6.78M |
